DelveInsight’s, Non-Small-Cell Lung cancer Pipeline Insight, 2023,” report provides comprehensive insights about 135+ companies and 150+ pipeline drugs in Non-Small-Cell Lung cancer pipeline landscape. It covers the pipeline drug profiles, including Non-Small-Cell Lung cancer clinical trials and nonclinical stage products. It also covers the Non-Small-Cell Lung cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
In the Non-Small-Cell Lung cancer Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Non-Small-Cell Lung cancer NDA approvals (if any), and product development activities comprising the technology, Non-Small-Cell Lung cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key takeaways from the Non-Small-Cell Lung cancer Pipeline Report
- DelveInsight’s Non-Small-Cell Lung Cancer pipeline report depicts a robust space with 135+ active players working to develop 150+ pipeline therapies for Non-Small-Cell Lung Cancer treatment.
- The leading Non-Small-Cell Lung Cancer Companies includes BridgeBio Pharma, Daiichi Sankyo, EMD Serono/Merck, BridgeBio Pharma, Abbvie/Pfizer, Eli Lilly and Company, BioNTech SE, Shenzhen TargetRx, Taiho Pharmaceutical, Chong Kun Dang, Bristol Myers Squibb, Innovent Biologics, Xuanzhu Biopharmaceutical, Bayer, GeneScience Pharmaceuticals, InventisBio, Apollomics, Imugene, and others.
- Promising Non-Small-Cell Lung Cancer Pipeline Therapies includes Trastuzumab deruxtecan, DS-1062a, M7824, Durvalumab, Patritumab Deruxtecan (Fixed dose), Sulijia, Exisulind, ONO-4538, Eribulin mesylate (eribulin; E7389), AZD9291 80 mg/40 mg, Lenvatinib, and others.
- The Non-Small-Cell Lung Cancer Companies and academics are working to assess challenges and seek opportunities that could influence Non-Small-Cell Lung cancer R&D. The Non-Small-Cell Lung Cancer pipeline therapies under development are focused on novel approaches to treat/improve Non-Small-Cell Lung cancer.
To explore more information on the latest breakthroughs in the Non-Small-Cell Lung Cancer Pipeline treatment landscape of the report, click here @ Non-Small-Cell Lung Cancer Pipeline Outlook
Non-Small-Cell Lung Cancer Overview
Non-small-cell lung cancer (NSCLC) is any type of epithelial lung cancer other than small-cell lung cancer (SCLC) and accounts for about 85% of all lung cancers. There are three kinds of NSCLC tumors: a) Adenocancer starts in cells inside air sacs that make mucus and other substances, often in the outer parts of your lungs. It’s the most common kind of lung cancer among both smokers and nonsmokers and people under 45. It often grows more slowly than other lung cancers. b) Squamous cell lung cancer starts in cells that line the inner airways of the lungs. About a quarter of lung cancers are this kind. c) Large cell (undifferentiated) cancer grows and spreads more quickly. That can make it tougher to treat. It’s about 10% of lung cancers. An effective treatment for non-small cell adenocancer depends on the cancer’s stage. Surgery to remove all or only part of the lung is usually required if the cancer hasn’t spread.
Recent Developmental Activities in the Non-Small-Cell Lung Cancer Treatment Landscape
- In May 2022, BridgeBio Pharma and Bristol Myers Squibb (BMS) have entered an exclusive licence agreement for developing and marketing BBP-398 in oncology. An inhibitor of SHP2, BBP-398 was created through a partnership with the Therapeutics Discovery division of The University of Texas MD Anderson Cancer Center, US. Under the deal, BMS will make upfront and milestone payments of up to $905m to BridgeBio.
For further information, refer to the detailed Non-Small-Cell Lung cancer Unmet Needs, Non-Small-Cell Lung cancer Market Drivers, and Non-Small-Cell Lung cancer Market Barriers, click here for Non-Small-Cell Lung cancer Ongoing Clinical Trial Analysis
Non-Small-Cell Lung cancer Emerging Drugs Profile
Datopotamab deruxtecan: Daiichi Sankyo
Datopotamab deruxtecan (Dato-DXd) is an investigational TROP2 directed ADC. Designed using Daiichi Sankyo’s proprietary DXd ADC technology, datopotamab deruxtecan is one of three leading ADCs in the oncology pipeline of Daiichi Sankyo, and one of the most advanced programs in AstraZeneca’s ADC scientific platform. Datopotamab deruxtecan is comprised of a humanized anti-TROP2 IgG13 monoclonal antibody, developed in collaboration with Sapporo Medical University, attached to a number of topoisomerase I inhibitor payloads, an exatecan derivative, via tetrapeptide-based cleavable linkers.
JDQ443: Novartis
JDQ443, an investigational selective, covalent, and orally bioavailable KRASG12C inhibitor, shows 57% confirmed ORR at recommended dose of 200 mg twice daily in Phase Ib study in patients with advanced non-small cell lung cancer (NSCLC).
MRTX849: Mirati Therapeutics
Adagrasib (MRTX849) is an investigational, highly selective, and potent oral small-molecule inhibitor of KRASG12C that is optimized to sustain target inhibition, an attribute that could be important to treat KRASG12C-mutated cancers, as the KRASG12C protein regenerates every 24–48 hours. Adagrasib is being evaluated as monotherapy and in combination with other anti-cancer therapies in patients with advanced KRASG12C-mutated solid tumors, including NSCLC, colorectal cancer and pancreatic cancer.
INBRX-106: Inhibrx
INBRX-106 is a hexavalent product candidate agonist of OX40. OX40 is a co-stimulatory receptor expressed on immune cells that is enriched in the tumor microenvironment. OX40 ligand is a trimeric protein that activates OX40 signaling through clustering. INBRX-106 was engineered to bind and cluster six OX40 receptors and has been shown preclinically to significantly outperform bivalent antibodies in co-stimulatory capacity and anti-tumor activity.
Non-Small-Cell Lung Cancer Pipeline Therapeutics Assessment
There are approx. 135+ key companies which are developing the therapies for Non-Small-Cell Lung cancer. The companies which have their Non-Small-Cell Lung cancer drug candidates in the most advanced stage, i.e. Phase III include Daiichi Sankyo.
Request a sample and discover the recent advances in Non-Small-Cell Lung Cancer Ongoing Clinical Trial Analysis and Medications, click here @ Non-Small-Cell Lung Cancer Treatment Landscape
Scope of the Non-Small-Cell Lung Cancer Pipeline Insight Report
- Coverage- Global
- Non-Small-Cell Lung Cancer Companies- BridgeBio Pharma, Daiichi Sankyo, EMD Serono/Merck, BridgeBio Pharma, Abbvie/Pfizer, Eli Lilly and Company, BioNTech SE, Shenzhen TargetRx, Taiho Pharmaceutical, Chong Kun Dang, Bristol Myers Squibb, Innovent Biologics, Xuanzhu Biopharmaceutical, Bayer, GeneScience Pharmaceuticals, InventisBio, Apollomics, Imugene, and others.
- Non-Small-Cell Lung Cancer Pipeline Therapies- Trastuzumab deruxtecan, DS-1062a, M7824, Durvalumab, Patritumab Deruxtecan (Fixed dose), Sulijia, Exisulind, ONO-4538, Eribulin mesylate (eribulin; E7389), AZD9291 80 mg/40 mg, Lenvatinib, and others.
- Non-Small-Cell Lung Cancer Pipeline Segmentation: Product Type, Molecule Type, Route of Administration, Mechanism of Action
Dive deep into rich insights for drugs for Non-Small-Cell Lung Cancer Market Drivers and Non-Small-Cell Lung Cancer Market Barriers, click here @ Non-Small-Cell Lung Cancer Unmet Needs and Analyst Views
Table of Content
- Introduction
- Executive Summary
- Non-Small-Cell Lung cancer: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Non-Small-Cell Lung cancer DelveInsight’s Analytical Perspective
- Mid Stage Products (Phase III)
- Datopotamab deruxtecan: Daiichi Sankyo
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- RMC-4630: REVOLUTION Medicines
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- GB 1211: BridgeBio Pharma
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- BBP 398: BridgeBio Pharma.
- Drug profiles in the detailed report…..
- Preclinical Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Non-Small-Cell Lung cancer Key Companies
- Non-Small-Cell Lung cancer Key Products
- Non-Small-Cell Lung cancer- Unmet Needs
- Non-Small-Cell Lung cancer- Market Drivers and Barriers
- Non-Small-Cell Lung cancer- Future Perspectives and Conclusion
- Non-Small-Cell Lung cancer Analyst Views
- Non-Small-Cell Lung cancer Key Companies
- Appendix
Got Queries? Find out the related information on Non-Small-Cell Lung Cancer Mergers and acquisitions, Non-Small-Cell Lung Cancer Licensing Activities @ Non-Small-Cell Lung Cancer Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services